US DEPARTMENT OF HEALTH AND HUMAN SERVICES: Mental health: a report of the Surgeon General. Rockville. (1999). Available at http://www.surgeongeneral.gov/library/ reports.htm
BIEDERMAN, 2005, Lancet, 366, 237, 10.1016/S0140-6736(05)66915-2
FARAONE, 2003, World Psychiatry, 2, 104
BIEDERMAN, 1998, J. Clin. Psychiatry, 59, 4, 10.4088/JCP.v59n1111
SANTOSH, 2000, Eur. Child Adolesc. Psychiatry, 9, I/27, 10.1007/s007870070017
TAYLOR, 2004, Eur. Child Adolesc. Psychiatry, 13, I/7, 10.1007/s00787-004-1002-x
NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE: Guidance on the use of methylphenidate for attention deficit hyperactivity disorder in childhood. (2001):13.
SCOTTISH INTERCOLLEGIATE GUIDELINES NETWORK: Attention deficit and hyperkinetic disorder in children and young people. (2001):52.
DOBSON, 2000, Br. Med. J., 321, 1100, 10.1136/bmj.321.7269.1100
PLISZKA, 2006, J. Am. Acad. Child Adolesc. Psychiatry, 45, 642, 10.1097/01.chi.0000215326.51175.eb
SANTOSH, 2005, Clinical Neuroscience Research, 5, 307, 10.1016/j.cnr.2005.09.010
SCHACHTER, 2001, CMAJ, 165, 1475
KLASSEN, 1999, Can. J. Psychiatry, 44, 1007, 10.1177/070674379904401007
10.1080/00221309.1983.9711481
OTTENBACHER, 1983, Dev. Med. Child Neurol., 25, 358, 10.1111/j.1469-8749.1983.tb13772.x
KAVALE, 1982, J. Learn. Disabil., 15, 280, 10.1177/002221948201500508
SPENCER, 1996, J. Am. Acad. Child Adolesc. Psychiatry, 35, 409, 10.1097/00004583-199604000-00008
SWANSON, 1993, Except. Child., 154, 10.1177/001440299306000209
THE, 1999, Arch. Gen. Psychiatry, 56, 1073, 10.1001/archpsyc.56.12.1073
CLAXTON, 2001, Clin. Ther., 23, 1296, 10.1016/S0149-2918(01)80109-0
BRITISH MEDICAL ASSOCIATION: British National Formulary, No. 51. Royal Pharmaceutical Society of Great Britain. London, UK (2006).
GREENHILL, 2002, J. Am. Acad. Child Adolesc. Psychiatry, 41, 26S, 10.1097/00004583-200202001-00003
BERKOVITCH, 1995, Clin. Pharmacol. Ther., 57, 696, 10.1016/0009-9236(95)90233-3
BIEDERMAN, 2000, Eur. Child Adolesc. Psychiatry, 9, I/51, 10.1007/s007870070019
BANASCHEWSKI, 2004, Eur. Child Adolesc. Psychiatry, 13, I/102, 10.1007/s00787-004-1010-x
EISENBERG, 1961, Am. J. Orthopsychiatry, 33, 431, 10.1111/j.1939-0025.1963.tb00377.x
GREENHILL, 1999, J. Am. Acad. Child Adolesc. Psychiatry, 38, 503, 10.1097/00004583-199905000-00011
SWANSON, 1995, N. Engl. J. Med., 333, 944, 10.1056/NEJM199510053331419
SOLANTO, 2002, Behav. Brain Res., 130, 65, 10.1016/S0166-4328(01)00431-4
VOLKOW, 2005, Biol. Psychiatry., 57, 1410, 10.1016/j.biopsych.2004.11.006
SHAYWITZ, 1982, Pediatrics, 69, 688, 10.1542/peds.69.6.688
SWANSON, 1978, Pediatrics, 61, 21, 10.1542/peds.61.1.21
GUALTIERI, 1982, J. Am. Acad. Child Psychiatry, 21, 19, 10.1097/00004583-198201000-00005
WARGIN, 1983, J. Pharmacol. Exp. Ther., 226, 382
PATRICK K, MUELLER R, GUALTIERI C: Pharmacokinetics and actions of methylphenidate. In:Psychopharmacology: a Third Generation of Progress. Meltzer H (Ed.), Raven Press, New York, NY, USA (1987):1387-1395.
SWANSON, 2002, Behav. Brain Res., 130, 73, 10.1016/S0166-4328(01)00433-8
PEREL, 1991, Clin. Pharmacol. Ther., 49, 160
GREENHILL, 1992, Psychiatr. Clin. North Am., 15, 1, 10.1016/S0193-953X(18)30255-7
PATRICK, 1997, Hum. Psychopharmacol., 12, 527, 10.1002/(SICI)1099-1077(199711/12)12:6<527::AID-HUP932>3.0.CO;2-U
GREENHILL, 1999, Ritalin: Theory and Practice
SWANSON, 1999, Clin. Pharmacol. Ther., 66, 295, 10.1016/S0009-9236(99)70038-X
WIGAL, 1999, Ment. Retard. Dev. Disabil. Res. Rev., 5, 215, 10.1002/(SICI)1098-2779(1999)5:3<215::AID-MRDD8>3.0.CO;2-K
SWANSON, 2003, Arch. Gen. Psychiatry, 60, 204, 10.1001/archpsyc.60.2.204
JANSSEN-CILAG LTD: Summary of product characteristics. (2002). Available at http://www.emc.medicines.org.uk
WOLRAICH, 2001, Pediatrics, 108, 883, 10.1542/peds.108.4.883
SWANSON, 2004, Pediatrics, 113, e206, 10.1542/peds.113.3.e206
MODI, 2000, J. Clin. Pharmacol., 40, 379, 10.1177/00912700022009080
MODI, 2000, J. Clin. Pharmacol., 40, 379, 10.1177/00912700022009080
MODI, 2000, Biopharm. Drug Dispos., 21, 23, 10.1002/1099-081X(200001)21:1<23::AID-BDD212>3.0.CO;2-V
AUILER, 2002, Curr. Med. Res. Opin., 18, 311, 10.1185/030079902125000840
MARKOWITZ, 2003, Clin. Pharmacokinet., 42, 393, 10.2165/00003088-200342040-00007
GONZALEZ, 2002, Int. J. Clin. Pharmacol. Ther., 40, 175, 10.5414/CPP40175
STEIN, 2003, Pediatrics, 112, e404, 10.1542/peds.112.5.e404
JACOBSON, 1991, J. Consult Clin. Psychol., 59, 12, 10.1037/0022-006X.59.1.12
STEELE, 2006, Can. J. Clin. Pharmacol., 13, e50
WILENS, 2005, J. Am. Acad. Child Adolesc. Psychiatry, 44, 1015, 10.1097/01.chi.0000173291.28688.e7
SWANSON, 2000, J. Clin. Res., 3, 59
BAREN, 2000, Proceedings of the Pediatric Academic Societies and American Academy of Pediatric Joint Meeting – May 12-16
REMSCHMIDT, 2005, Eur. Child Adolesc. Psychiatry, 14, 297, 10.1007/s00787-005-0467-6
WILENS, 2006, Archives of Pediatric Adolescent Medicine, 160, 82, 10.1001/archpedi.160.1.82
BIEDERMAN, 2006, Biol. Psychiatry, 59, 829, 10.1016/j.biopsych.2005.09.011
BIEDERMAN, 2006, CNS Spectr., 11, 390, 10.1017/S1092852900014528
SONUGA-BARKE, 2004, BMC Psychiatry, 4, 28, 10.1186/1471-244X-4-28
KEMNER, 2005, Adv. Ther., 22, 498, 10.1007/BF02849870
NEWCORN, 2005, 45th Annual Meeting of the New Clinical Drug Evaluation Unit – June 6-9
BANASCHEWSKI, 2006, Eur. Child Adolesc. Psychiatry
COX, 2004, J. Am. Board Fam. Pract., 17, 235, 10.3122/jabfm.17.4.235
COX, 2004, J. Am. Acad. Child Adolesc. Psychiatry, 43, 269, 10.1097/00004583-200403000-00007
LAGE, 2004, J. Child Adolesc. Psychopharmacol., 14, 575, 10.1089/cap.2004.14.575
WILENS, 2003, J. Am. Acad. Child Adolesc. Psychiatry, 42, 424, 10.1097/01.CHI.0000046814.95464.7D
DENCKLA, 1976, JAMA, 235, 1349, 10.1001/jama.1976.03260390035024
LIPKIN, 1994, Arch. Pediatr. Adolesc. Med., 148, 859, 10.1001/archpedi.1994.02170080089017
PALUMBO, 2004, J. Child Adolesc. Psychopharmacol., 14, 185, 10.1089/1044546041649138
SWANSON, 2000, Pediatr. Res., 47, 34A
WILENS, 2003, Pediatrics, 111, 179, 10.1542/peds.111.1.179
SPENCER, 2005, Biol. Psychiatry, 57, 1293, 10.1016/j.biopsych.2005.03.036
WILENS, 2004, Clinical Focus, 11, 63
